BVF portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
BVF reported a $3.9 bn portfolio of 44 positions to the SEC as of the end of Q2 2026. Its largest positions are RVMD, KYMR, XOMA Royalty. During the quarter it opened Q32 Bio and Absci and exited Compass Therapeutics and Septerna.
Sections with a free account
What changed this quarter
21 positions with a change (4 new, 6 added to, 9 trimmed, 2 sold); also, 2 entered through an IPO, 1 exited through an acquisition or merger. 9 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- XOMA Royalty+193%more sharesIncreased2.6% → 8.3%
- Kymera Therapeutics−30%fewer sharesReduced14.6% → 11.4%
- Mirum Pharmaceuticals−33%fewer sharesReduced4.7% → 3.2%
- Palvella Therapeutics−30%fewer sharesReduced3.8% → 2.6%
- Compass Therapeutics−1.1 ppof portfolioSold out1.3% → —
- Septerna−0.8 ppof portfolioSold out1.0% → —
- Q32 Bio+0.8 ppof portfolioNew— → 0.8%
- Absci+0.7 ppof portfolioNew— → 0.7%
- Revolution Medicines+3.8%more sharesIncreased8.9% → 14.2%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Revolution MedicinesRVMD14.2%
- Kymera TherapeuticsKYMR11.4%
- XOMA Royalty8.3%
- Moonlake ImmunotherapeuticsMLTX8.0%
- GH ResearchGHRS5.9%
- Structure TherapeuticsGPCR4.6%
- Nektar TherapeuticsNKTR4.3%
- Mirum PharmaceuticalsMIRM3.2%
- XencorXNCR2.9%
- Alkermes plc.ALKS2.9%
- Monte Rosa TherapeuticsGLUE2.8%
- Cullinan TherapeuticsCGEM2.7%
- Palvella TherapeuticsPVLA2.6%
- ZymeworksZYME2.4%
- KURA OncologyKURA2.4%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 44
Q2 2026: 66%
Q2 2026: 9.7%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- C WorldWide Group Holding A/SInvestment firm · $4.0 bn
- Marsico Capital ManagementInvestment firm · $3.8 bn
- XNInvestment firm · $3.8 bn
- PAR Capital ManagementInvestment firm · $4.0 bn
- Hamlin Capital ManagementInvestment firm · $4.0 bn
- Oaktree Capital ManagementInvestment firm · $3.8 bn